TOXIC EPIDERMAL NECROLYSIS (LYELL’S SYNDROME)

1. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. / Br J Dermatol 1956; 68(11): 355–61.

2. Valeyrie-Allanore L., Roujeau Jean-Claude. Epidermal necrolysis (Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis). In: Wolf K. et al. Fitzpatrick’s dermatology in general medicine 7th edition, New York: МсGraw-Hill, 2008; 349-355.

3. Roujeau J.C., Guillaume J.C., Fabre J.D. Toxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in France, 1981-85. / Arch Dermatol 1990; 126(1): 37-42.

4. Saiag P. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immudeficiency virus. / J Am Acad Dermatol 1992; 26(4): 567-74.

5. French LE., Prins C. Erythema multiforme, StevensJohnson syndrome and toxic epidermal necrolysis. / In: Bolognia JL, Jorrizo JL, Schaffer JV editors. Dermatology 3rd edition, New York: Elsevier; 2013; 319–33.

6. Bastuji-Garin S., Rzany B., Stern R.S. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. / Arch Dermatol 1993; 129(1): 92–6.

7. Chen P., Lin J.J., Lu C.S. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. / N Engl J Med 2011; 364(12): 1126–33.

8. Hung S.I., Chung W.H., Liou L.B. HLA-B5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. / Proc Natl Acad Sci USA 2005; 102(11): 4134–9.

9. Revuz J., Penso D., Roujeau J.C. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. / Arch Dermatol 1987; 123(9): 1160–5.

10. Ang C.C., Tay Y.K. / Hematological abnormalities and the use of granulocyte-colony-stimulating factor in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. / Int J Dermatol 2011; 50(12): 1570–8.

11. Lebargy F., Wolkenstein P., Gisselbrecht M. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. / Intensive Care Med 1997; 23(12): 1237–44.

12. Chang Y.S., Huang F.C., Tseng S.H. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. / Cornea 2007; 26(2): 123–9.

13. Yip L.W., Thong B.Y., Lim J. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. / Allergy 2007; 62(5): 527–31.

14. Magina S., Lisboa C., Leal V. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. / Dermatology 2003; 207(1): 33–6.

15. Chosidow O., Delchier J.C., Chaumette M.T. / Intestinal involvement in drug-induced toxic epidermal necrolysis. Lancet 1991, 337: 928.

16. Paquet P., Pierard G.E. Erytema multiforme and toxic epidermal necrolysis: a comparative study. / Am J Dermatophatol 1997; 19(2): 127-32.

17. Schwartz R.A., McDonough P.H., Lee B.W. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. / J Am Acad Dermatol 2013; 69(2): 187.e1–16; quiz 203–4.

18. Rzany B., Schmitt H., Schαpf E. Toxic epidermal necrolysis in patient receiving glucocorticosteroids. / Acta Derm Venerol (Stockh) 1991; 71: 171-2.

19. Van der Meer J.B., Schuttelaar M.L., Toth G.G. Successful dexamethasone pulse therapy in a toxic epidermal necrolysis (TEN) patient featuring recurrent TEN to oxazepam. / Clin Exp Dermatol 2001; 26: 654-6.

20. Han F., Zhang J. Successful treatment of toxic epidermal necrolysis using plasmapheresis: A prospective observational study. / J Crit Care 2017; 1(42): 65-68.

21. Barron S.J., Del Vecchio M.T., Aronoff S.C. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with metaregression of observational studies. / Int J Dermatol 2015; 54(1): 108–15.

22. Huang Y.C., Li Y.C., Chen T.J. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. / Br J Dermatol 2012; 167(2): 424–32.

23. Roujeau J.C., Mockenhaupt M., Guillaume J.C., Revuz J. New Evidence Supporting Cyclosporine Efficacy in Epidermal Necrolysis. / J Invest Dermatol 2017; 137(10): 2047-2049.

24. Fischer M., Fiedler E., Marsch W.C. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. / J Br J Dermatol 2002; 146(4): 707-9.